Bill Detail
An Act to amend the Food and Drugs Act (List of Therapeutic Products Pre-approved for Special Access)
BillC-265
Session45-1
StageIn committee (House)
Introduced2026-03-11
Proposed byMarcus Powlowski
This enactment requires the Minister of Health to develop a national strategy to support perinatal mental health across Canada. It also provides for reporting requirements in relation to the strategy.
✦ AI Summary
Bill C-265 proposes to create a special list of therapeutic products that are pre-approved for "special access". This means patients with serious, life-threatening, or rare conditions, or those for whom no comparable treatment exists in Canada, could get faster access to needed medications. The bill outlines how the Minister of Health will decide which products go on the list, ensuring they meet quality and safety standards, and specifies conditions for their use.
Generated by Gemini · may contain errors
Legislative Timeline
2026-03-11
First reading
✦ AIBill proposes streamlined special access to pre-approved therapeutic products.
Current
In committee (House)
✦ AIBill is currently under review by a House of Commons committee.
Votes
Vote #: 120
Date: 2021-05-26
Result: Passed
Yes: 181
No: 150
Yes / No Ratio
Yes54.7%
No45.3%
How each party voted
| Party | Position | Yes | No |
|---|---|---|---|
| Bloc | Yes | 100% | 0% |
| Conservative | Yes | 100% | 0% |
| Green | Yes | 100% | 0% |
| Liberal | No | 0% | 100% |
| NDP | Yes | 100% | 0% |